For patients seeking medications that aid in weight loss and improve cardiovascular health, semaglutide and tirzepatide are powerful tools
Patients should contact their GP or prescribing clinician if they experience: Severe or persistent cramps that do not respond to simple measures or significantly impact daily activities and sleep quality Frequent cramping occurring multiple times daily or nightly Associated symptoms such as muscle weakness, numbness, tingling, or changes in sensation, which may indicate neurological involvement Visible muscle changes including swelling, redness, tenderness, or asymmetry between legs Signs of dehydration such as dizziness, reduced urine output, dark urine, or confusion These features may indicate underlying conditions requiring investigation, such as significant electrolyte disturbances, peripheral neuropathy (particularly relevant in diabetes), peripheral arterial disease, or, rarely, more serious muscle disorders
The positive Phase 3 data may also be used for filings in other regions with a high prevalence of obesity
Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors
Most healthcare providers follow established clinical protocols when prescribing GLP-1 medications, including gradual dose titration to help reduce the likelihood of digestive side effects
Its like hitting restart on a video game